ANAB ANAPTYSBIO, INCcompanySEC Filings & Insider Trading Activity 2026
Latest ANAPTYSBIO, INC (ANAB) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 3, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on April 24, 2026, Form 4 insider transactions reported on April 22, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ANAPTYSBIO, INC (ANAB) (SEC CIK 1370053), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Business model: Biopharma company focusing on clinical development and commercialization collaborations, recognizing revenue mainly from milestones and royalties, not product sales
- • New monetization deals in 2024: Sold additional Jemperli royalty receivables for $50M, expanding prior $250M monetization agreement with Sagard
Risk Factors
- • FDA acceptance of Vanda's imsidolimab BLA for GPP with target action date December 12, 2026, creating regulatory milestone risk
- • Exposure to global macroeconomic shifts impacting 424-patient rosnilimab Phase 2b RA trial conducted worldwide
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New regulatory risk from June 2024 U.S. Supreme Court decision reversing Chevron doctrine, increasing uncertainty in FDA regulatory reviews
- • Most materially updated risk: ongoing Phase 2 trials of rosnilimab may show differing efficacy or safety, impacting development timelines and success
Annual Reports Archive10-K
AI-powered analysis of ANAPTYSBIO, INC (ANAB) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of ANAPTYSBIO, INC (ANAB) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ANAPTYSBIO, INC (ANAB) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $10.3M | $17.2M | $91.3M | $234.6M |
| Operating Income | -$115.2M | -$164.4M | -$114.9M | $47.9M |
| Net Income | -$128.7M | -$163.6M | -$145.2M | -$13.2M |
| Op. Margin | -1119.4% | -958.3% | -125.9% | 20.4% |
| Net Margin | -1251.3% | -953.7% | -159.1% | -5.6% |
| Balance Sheet | ||||
| Total Assets | $610.4M | $452.4M | $483.8M | $364.4M |
| Equity | $262.1M | $88.1M | $70.9M | $37.2M |
| ROE | -49.1% | -185.7% | -204.9% | -35.6% |
Source: XBRL financial data from ANAPTYSBIO, INC (ANAB) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 24, 2026 | — | — | — |
4 | Apr 22, 2026 | — | — | — |
8-K | Apr 20, 2026 | — | — | — |
8-K | Mar 27, 2026 | — | — | — |
10-K | Mar 3, 2026 | Dec 31, 2025 | Analysis | |
8-K | Mar 3, 2026 | — | Analysis | — |
8-K | Jan 9, 2026 | — | — | |
8-K | Nov 26, 2025 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 5, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 5, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 5, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Mar 11, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | — | |
10-Q | May 11, 2023 | Mar 31, 2023 | — | |
10-K | Mar 1, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 8, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Mar 7, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — |
Frequently Asked Questions
What are the latest ANAB SEC filings in 2026?
ANAPTYSBIO, INC (ANAB) has filed a 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 24, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ANAB file its most recent 10-K annual report?
ANAPTYSBIO, INC (ANAB) filed its most recent 10-K annual report on March 3, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ANAB 10-Q quarterly reports?
ANAPTYSBIO, INC (ANAB)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every ANAB 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ANAB filed recently?
ANAPTYSBIO, INC (ANAB)'s most recent 8-K was filed on April 24, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ANAB insider trading activity (Form 4)?
The most recent ANAB Form 4 insider transaction on SignalX was filed on April 22, 2026. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock. SignalX aggregates every ANAB Form 4 with transaction code, share count, and price per share.
How often does ANAB file with the SEC?
ANAPTYSBIO, INC (ANAB) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ANAB filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ANAPTYSBIO, INC (ANAB).
What is ANAB's SEC CIK number?
ANAPTYSBIO, INC (ANAB)'s SEC CIK (Central Index Key) number is 1370053. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1370053 to look up all ANAB filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ANAB return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ANAPTYSBIO, INC (ANAB) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ANAPTYSBIO, INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 42+ filings.